Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Pempro Pemetrexed Injection IP 500 mg
Pempro, provided by Lexaro Healthcare, contains 500 mg of Pemetrexed in each injection. This formulation is designed to provide effective treatment for certain types of cancer, including malignant pleural mesothelioma and non-small cell lung cancer.
Uses of Pempro Pemetrexed Injection IP 500 mg
Pempro is primarily prescribed for the treatment of malignant pleural mesothelioma, in combination with cisplatin, in patients who are not candidates for surgery. It is also used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy treatment.
Benefits of Pempro Pemetrexed Injection IP 500 mg
Provides effective treatment for malignant pleural mesothelioma.
Used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC).
Can be used in combination with other chemotherapeutic agents for enhanced efficacy.
Helps to slow the growth and spread of cancer cells.
Administered by healthcare professionals ensuring proper dosage and monitoring.
Well-tolerated with a favorable safety profile when used as directed.
Mechanism of Action of Pempro Pemetrexed Injection IP 500 mg
Pemetrexed is a multi-targeted antifolate that works by inhibiting several key enzymes involved in the folate-dependent metabolic processes essential for cell replication. These enzymes include thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT). By inhibiting these enzymes, Pemetrexed disrupts DNA and RNA synthesis, leading to the death of rapidly dividing cancer cells. This mechanism helps to control the growth and spread of cancer, providing a targeted treatment approach for patients with malignant pleural mesothelioma and non-small cell lung cancer.